Current status of basic and clinical research on metformin in endometrial cancer

Abstract

Zhao Xiaoling, Kong Weimin. Current status of basic and clinical research on metformin in endometrial cancer[J]. Journal of International Oncology, 2020, 47(7): 440-443.

References26

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. pmid:30207593
[2]	Moore K, Brewer MA. Endometrial cancer: is this a new disease?[J]. Am Soc Clin Oncol Educ Book, 2017,37:435-442. DOI: 10.1200/EDBK_175666. pmid:28561715
[3]	Gonthier C, Trefoux-Bourdet A, Luton D, et al. Fertility-sparing management of endometrial cancer and atypical hyperplasia[J]. Gynecol Obstet Fertil Senol, 2017,45(2):112-118. DOI: 10.1016/j.gofs.2016.12.011. pmid:28368791
[4]	Lee TY, Martinez-Outschoorn UE, Schilder RJ, et al. Metformin as a therapeutic target in endometrial cancers[J]. Front Oncol, 2018,8:341. DOI: 10.3389/fonc.2018.00341. doi:10.3389/fonc.2018.00341pmid:30211120
[5]	Chu D, Wu J, Wang K, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2018,18(1):438. DOI: 10.1186/s12885-018-4334-5. pmid:29669520
[6]	Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis[J]. Gynecol Oncol, 2017,147(1):167-180. DOI: 10.1016/j.ygyno.2017.07.120. doi:10.1016/j.ygyno.2017.07.120pmid:28760367
[7]	Morales DR, Morris AD. Metformin in cancer treatment and prevention[J]. Annu Rev Med, 2015,66:17-29. DOI: 10.1146/annurev-med-062613-093128. doi:10.1146/annurev-med-062613-093128pmid:25386929
[8]	Tian W, Teng F, Zhao J, et al. Estrogen and insulin synergistically promote type 1 endometrial cancer progression[J]. Cancer Biol Ther, 2017,18(12):1000-1010. DOI: 10.1080/15384047.2017.1394547. doi:10.1080/15384047.2017.1394547pmid:29172956
[9]	Collins G, Mesiano S, DiFeo A. Effects of metformin on cellular proliferation and steroid hormone receptors in patient-derived, low-grade endometrial cancer cell lines[J]. Reprod Sci, 2018,1:1933719118779734. DOI: 10.1177/1933719118779734.
[10]	Zhang J, Xu H, Zhou X, et al. Role of metformin in inhibiting estrogen-induced proliferation and regulating ERα and ERβ expression in human endometrial cancer cells[J]. Oncol Lett, 2017,14(4):4949-4956. DOI: 10.3892/ol.2017.6877. doi:10.3892/ol.2017.6877pmid:29085506
[11]	Zhang HH, Guo XL. Combinational strategies of metformin and chemotherapy in cancers[J]. Cancer Chemother Pharmacol, 2016,78(1):13-26. DOI: 10.1007/s00280-016-3037-3. doi:10.1007/s00280-016-3037-3pmid:27118574
[12]	Wallbillich JJ, Josyula S, Saini U, et al. High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: therapeutic implications for endometrial cancer[J]. PLoS One, 2017,12(1):e0170318. DOI: 10.1371/journal.pone.0170318. pmid:28114390
[13]	Tabrizi AD, Melli MS, Foroughi M, et al. Antiproliferative effect of metformin on the endometrium-a clinical trial[J]. Asian Pac J Cancer Prev, 2014,15(23):10067-10070. DOI: 10.7314/apjcp.2014.15.23.10067. doi:10.7314/apjcp.2014.15.23.10067pmid:25556427
[14]	Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis[J]. Gynecol Oncol, 2017,147(1):167-180. DOI: 10.1016/j.ygyno.2017.07.120. doi:10.1016/j.ygyno.2017.07.120pmid:28760367
[15]	Davis SR, Robinson PJ, Jane F, et al. The benefits of adding metformin to tamoxifen to protect the endometrium—a randomized placebo-controlled trial[J]. Clin Endocrinol (Oxf), 2018,89(5):605-612. DOI: 10.1111/cen.13830. doi:10.1111/cen.2018.89.issue-5
[16]	Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help[J]. Gynecol Oncol, 2014,132(1):248-253. DOI: 10.1016/j.ygyno.2013.10.028. pmid:24183733
[17]	Chu D, Wu J, Wang K, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2018,18(1):438. DOI: 10.1186/s12885-018-4334-5. doi:10.1186/s12885-018-4334-5pmid:29669520
[18]	Xie W, Li T, Yang J, et al. Metformin use and survival outcomes in endometrial cancer: a systematic review and meta-analysis[J]. Oncotarget, 2017,8(42):73079-73086. DOI: 10.18632/oncotarget.20388. doi:10.18632/oncotarget.20388pmid:29069850
[19]	Mitsuhashi A, Sato Y, Kiyokawa T, et al. Phase Ⅱ study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer[J]. Ann Oncol, 2016,27(2):262-266. DOI: 10.1093/annonc/mdv539. doi:10.1093/annonc/mdv539pmid:26578736
[20]	Ezewuiro O, Grushko TA, Kocherginsky M, et al. Association of metformin use with outcomes in advanced endometrial cancer treated with chemotherapy[J]. PLoS One, 2016,11(1):e0147145. DOI: 10.1371/journal.pone.0147145. doi:10.1371/journal.pone.0147145pmid:26788855
[21]	Hanna RK, Zhou C, Malloy KM, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway[J]. Gynecol Oncol, 2012,125(2):458-469. DOI: 10.1016/j.ygyno.2012.01.009. doi:10.1016/j.ygyno.2012.01.009pmid:22252099
[22]	王小慧, 张岩, 刘林枝, 等. 二甲双胍与脂联素对子宫内膜癌细胞增殖的作用[J]. 北京大学学报(医学版), 2018,50(5):767-773. DOI: 10.19723/j.issn.1671-167X.2018.05.001.
[23]	Dong L, Zhou Q, Zhang Z, et al. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase Ⅰ expression[J]. J Obstet Gynaecol Res, 2012,38(8):1077-1085. DOI: 10.1111/j.1447-0756.2011.01839.x. doi:10.1111/j.1447-0756.2011.01839.xpmid:22540333
[24]	Bai M, Yang L, Liao H, et al. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism[J]. Oncogene, 2018,37(42):5666-5681. DOI: 10.1038/s41388-018-0360-7. doi:10.1038/s41388-018-0360-7pmid:29921847
[25]	Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells[J]. J Steroid Biochem Mol Biol, 2011,126(3-5):113-120. DOI: 10.1016/j.jsbmb.2010.12.006. doi:10.1016/j.jsbmb.2010.12.006pmid:21168492
[26]	Mu N, Dong M, Li L, et al. Synergistic effect of metformin and medroxyprogesterone 17 acetate on the development of endometrial cancer[J]. Oncol Rep, 2018,39(4):2015-2021. DOI: 10.3892/or.2018.6236. doi:10.3892/or.2018.6236pmid:29393479

Current status of basic and clinical research on metformin in endometrial cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References26

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Fan Mengsi, Lu Yaping, Yan Li.Analysis of clinicopathologic features of false negative sentinel lymph nodes in patients with endometrial cancer[J]. Journal of International Oncology, 2023, 50(5): 274-279.
[2]	Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping.Research progress of metformin in non-Hodgkin lymphoma[J]. Journal of International Oncology, 2022, 49(7): 436-440.
[3]	Ning Tingting, Hu Qinyong.Research progress of metformin in tumor immunotherapy[J]. Journal of International Oncology, 2022, 49(5): 292-295.
[4]	Xu Qiuyue, Ma Xianmei, Yue Qi.Immunotherapy for endometrial carcinoma based on molecular typing[J]. Journal of International Oncology, 2022, 49(11): 700-704.
[5]	Deng Bo'er, Kong Weimin.Epigenetic research progress of endometrial cancer[J]. Journal of International Oncology, 2021, 48(3): 184-188.
[6]	Huang Yuting, Wang Chao.Anti-tumor effect of berberine hydrochloride combined with epirubicin and cisplatin on advanced endometrial carcinoma[J]. Journal of International Oncology, 2020, 47(9): 530-534.
[7]	Wang Xue, Ji Guoxin, Ji Chao, Yang Xingsheng.Effects of metformin on prognosis of type Ⅰ endometrial carcinoma patients complicated with type 2 diabetes mellitus[J]. Journal of International Oncology, 2020, 47(7): 404-408.
[8]	Zhou Luqiu, Liu Xianxi, Li Yan, Mao Xiguang.Analysis of prognostic risk factors of type Ⅰ endometrial cancer[J]. Journal of International Oncology, 2020, 47(6): 346-350.
[9]	Luo Chuncui, Yuan Chaoyan, Chen Qingfen.GOLPH3 regulates proliferation and apoptosis of endometrial carcinoma cells through PI3K/AKT/GSK3β signal[J]. Journal of International Oncology, 2020, 47(2): 65-69.
[10]	Liang Biyu, He Weiming, He Xiaoyi, Ding Yuanlin, Yu Haibing.Diabetes, hypoglycemic drugs and pancreatic cancer[J]. Journal of International Oncology, 2018, 45(3): 183-186.
[11]	Gao Hui, Yi Shanyong, Yang Bin, Ma Xiwen, Zhao Ling.Antitumor mechanism of metformin and its effect on targeted drugs[J]. Journal of International Oncology, 2018, 45(12): 747-750.
[12]	LI Mei-Yan.Clinical significance of detection of HE4, OPN and uPA in the diagnosis of endometrial carcinoma[J]. Journal of International Oncology, 2017, 44(5): 351-355.
[13]	ZHANG Xiao-Fei, WEI Ya-Qiang.Effect of different chemotherapy combined with radiotherapy for the treatment of nonsmall cell lung cancer complicated with type 2 diabetes[J]. Journal of International Oncology, 2017, 44(2): 95-98.
[14]	XIE Ze-Jun, TANG Yue, ZHOU Jing, DENG Jing-Huan, HE Min, LU Guo-Dong.Effect and mechanism of metformin combined with 2-deoxy-D-glucose on proliferation and apoptosis of liver cancer cells[J]. Journal of International Oncology, 2017, 44(2): 81-85.
[15]	Wan Lijuan, Chen Mingwei.Relationship between insulin resistance related factors and colon cancer stem cells[J]. Journal of International Oncology, 2017, 44(10): 790-793.